Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis

Journal of Medical Microbiology

Volumn 65, Issue 9, 2016, Pages 1038-1046

  De Moreno De Leblanc, Alejandra ^a   Del Carmen, Silvina ^a   Chatel, Jean Marc ^b   Azevedo, Vasco ^c   Langella, Philippe ^b   Bermudez Humaran, Luis ^b   Leblanc, Jean Guy ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b UMR1319 MICALIS   (France)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; INTERLEUKIN 10; LACTIC ACID; PROBIOTIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BIOSAFETY; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFECT; EXPERIMENTAL ULCERATIVE COLITIS; FEMALE; GASTROINTESTINAL TRACT; HEMATOLOGICAL PARAMETERS; HISTOLOGY; LACTIC ACID BACTERIUM; LACTOCOCCUS LACTIS; LARGE INTESTINE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; SMALL INTESTINAL TISSUE; STREPTOCOCCUS THERMOPHILUS; ADVERSE DRUG REACTION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL THERAPY; COLITIS; GENETICS; PATHOGENICITY; PROCEDURES;

ANIMAL EXPERIMENTATION; ANIMALS; BIOLOGICAL THERAPY; COLITIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; LACTOCOCCUS LACTIS; MICE, INBRED BALB C; PROBIOTICS; STREPTOCOCCUS THERMOPHILUS;

EID: 84989845477     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000323     Document Type: Article

References (29)

1. Basso, P. J., Fonseca, M. T., Bonf a, G., Alves, V. B., Sales-Campos, H., Nardini, V. & Cardoso, C. R. (2014). Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease. Braz J Med Biol Res 47, 727–737.
2. Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J. P., van Deventer, S. J., Neirynck, S., Peppelenbosch, M. P. & Steidler, L. (2006). A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol 4, 754–759.
3. De Greef, E., Vandenplas, Y., Hauser, B., Devreker, T. & Veereman, G. (2014). The use of probiotics in IBD and IBS. Minerva Pediatr 66, 491–500.
4. de Moreno de LeBlanc, A., LeBlanc, J. G., Perdigón, G., Miyoshi, A., Langella, P., Azevedo, V. & Sesma, F. (2008). Oral administration of a catalase-producing Lactococcus lactis can prevent a chemically induced colon cancer in mice. J Med Microbiol 57, 100–105.
5. de Moreno de LeBlanc, A., Chaves, S. & Perdigon, G. (2009). Effect of yoghhurt on the cytokine profile using a murine model of intestinal inflammation. Eur J Inflam 7, 97–109.
6. de Moreno de LeBlanc, A. & LeBlanc, J. G. (2014). Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications. World J Gastroenterol 20, 16518–161528.
7. de Moreno de LeBlanc, A., del Carmen, S., Chatel, J. M., Miyoshi, A., Azevedo, V., Langella, P., Bermúdez-Humar an, L. G. & LeBlanc, J. G. (2015). Current review of genetically modified lactic acid bacteria for the prevention and treatment of colitis using murine models. Gastroenterol Res Pract 2015, 10.1155/2015/146972
8. del Carmen, S., de Moreno de LeBlanc, A., Perdigon, G., Bastos Pereira, V., Miyoshi, A., Azevedo, V. & LeBlanc, J. G. (2012). Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing Lactococcus lactis using a murine model of Crohn’s disease. J Mol Microbiol Biotechnol 21, 138–146.
9. del Carmen, S., Leblanc, J. G. & de Moreno de Leblanc, A. (2013a). Use of probiotics in the treatment of Crohn’s disease. In Crohn’s Disease: Etiology, Diagnosis and Treatment Options. Edited by J. G. Leblanc & A. de Moreno de Leblanc. Hauppauge, NY: Nova Science Publishers, Inc.
10. del Carmen, S., Zurita-Turk, M., Alvarenga Lima, F., Coelho Dos Santos, J. S., Leclercq, S. Y., Chatel, J.-M., Azevedo, V., de Moreno de Leblanc, A., Miyoqhi, A. & Leblanc, J. G. (2013b). A novel interleukin-10 DNA mucosal delivery system attenuates intestinal inflammation in a mouse model. Eur J Inflamm 11, 641–655.
11. del Carmen, S., de Moreno de LeBlanc, A., Martin, R., Chain, F., Langella, P., Bermúdez-Humar an, L. G. & LeBlanc, J. G. (2014a). Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities. Appl Environ Microbiol 80, 869–877.
12. del Carmen, S., Martín Rosique, R., Saraiva, T., Zurita-Turk, M., Miyoshi, A., Azevedo, V., de Moreno de LeBlanc, A., Langella, P., Bermúdez-Humar an, L. G. & LeBlanc, J. G. (2014b). Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model. J Clin Gastroenterol 48, S12–S17.
13. del Carmen, S., Miyoshi, A., Azevedo, V., de Moreno de LeBlanc, A. & LeBlanc, J. G. (2015). Evaluation of a Streptococcus thermophilus strain with innate anti-inflammatory properties as a vehicle for IL-10 cDNA delivery in an acute colitis model. Cytokine 73, 177–183.
14. FAO/WHO (2001). Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report. Available from ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf
15. Gasson, M. J. (1983). Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 154, 1–9.
16. Laiño, J. E., Zelaya, H., Juarez del Valle, M., Savoy de Giori, G. & LeBlanc, J. G. (2015). Milk fermented with selected strains of lactic acid bacteria is able to improve folate status of deficient rodents and also prevent folate deficiency. J Func Foods 17, 22–32.
17. LeBlanc, J. G., Garro, M. S., Giori, G. S., Valdez, G. F., Savoy De Giori, G. & Font De Valdez, G. (2004). A novel functional soy-based food fermented by lactic acid bacteria: effect of heat treatment. J Food Sci 69, M246–M250.
18. LeBlanc, J. G., Van Sinderen, D., Hugenholtz, J., Piard, J. C., Sesma, F. & de Giori, G. S. (2010). Risk assessment of genetically modified lactic acid bacteria using the concept of substantial equivalence. Curr Microbiol 61, 590–595.
19. LeBlanc, J. G., Aubry, C., Cortes-Perez, N. G., de Moreno de LeBlanc, A., Vergnolle, N., Langella, P., Azevedo, V., Chatel, J. M., Miyoshi, A. & Bermúdez-Humar an, L. G. (2013a). Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol Lett 344, 1–9.
20. LeBlanc, J., Carmen, S., Turk, M., Lima, F., Pontes, D., Miyoshi, A., Azevedo, V. & de LeBlanc, A. (2013b). Mechanisms involved in the anti-inflammatory properties of native and genetically engineered lactic acid bacteria. Anti-Infective Agents 11, 59–69.
21. Limaye, S. A., Haddad, R. I., Cilli, F., Sonis, S. T., Colevas, A. D., Brennan, M. T., Hu, K. S. & Murphy, B. A. (2013). Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119, 4268–4276.
22. Luerce, T. D., Gomes-Santos, A. C., Rocha, C. S., Moreira, T. G., Cruz, D. N., Lemos, L., Sousa, A. L., Pereira, V. B., de Azevedo, M. & other authors (2014). Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis. Gut Pathog 6, 1–11.
23. Mandell, D. J., Lajoie, M. J., Mee, M. T., Takeuchi, R., Kuznetsov, G., Norville, J. E., Gregg, C. J., Stoddard, B. L. & Church, G. M. (2015). Bio-containment of genetically modified organisms by synthetic protein design. Nature 518, 55–60.
24. Martín, R., Chain, F., Miquel, S., Natividad, J. M., Sokol, H., Verdu, E. F., Langella, P. & Bermúdez-Humar an, L. G. (2014). Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. Hum Vaccin Immunother 10, 1611–1621.
25. Pontes, D., Innocentin, S., del Carmen, S., Almeida, J. F., Leblanc, J. G., de Moreno de Leblanc, A., Blugeon, S., Cherbuy, C., Lef evre, F. & other authors (2012). Production of fibronectin binding protein A at the surface of Lactococcus lactis increases plasmid transfer in vitro and in vivo. PLoS One 7, e44892.
26. Rovner, A. J., Haimovich, A. D., Katz, S. R., Li, Z., Grome, M. W., Gassaway, B. M., Amiram, M., Patel, J. R., Gallagher, R. R. & other authors (2015). Recoded organisms engineered to depend on synthetic amino acids. Nature 518, 89–93.
27. Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., Cox, E., Remon, J. P. & Remaut, E. (2003). Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 21, 785–789.
28. Sybesma, W., Hugenholtz, J., De Vos, W. M. & Smid, E. J. (2006). Safe use of genetically modified lactic acid bacteria in food. Bridging the gap between consumers, green groups, and industry. Elect J Biotechnol 9, 424–448.
29. Zurita-Turk, M., del Carmen, S., Santos, A. C., Pereira, V. B., Cara, D. C., Leclercq, S. Y., de LeBlanc, A., Azevedo, V., Chatel, J. M. & other authors (2014). Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis. BMC Biotechnol 14, 73.